Addex Therapeutics earnings date
Addex Therapeutics (APE1) Q2 2026 Earnings Report
DE:APE1 Q2 2026 EPS Results
- Actual EPS
- -EUR 1.31
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -EUR 2.74
DE:APE1 Q2 2026 Revenue Results
- Actual Revenue
- EUR 11.42K
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- -79.69%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 09/28/2026
- Time
- Before Open
- Conference Call
- Monday, September 28, 2026
Addex Therapeutics's next earnings date is estimated for March 11, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call was predominantly positive, highlighting a $2.8 million financing, cash runway into Q4 2027, regained rights to the GABAB PAM platform, multiple advancing preclinical and clinical programs, and encouraging chronic cough and substance use disorder data. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash use, a stable CHF 3.4 million net loss, increased share of Neurosterix losses, and the need to secure financing before advancing certain programs.
Addex said the GABAB PAM substance use disorder candidate is ready for IND filing and phase I clinical trials, with the next milestone being the filing of an IND, while IND enabling studies for the chronic cough program are “planned and ready to start subject to securing financing”; it expects phase I data from Neurosterix’s NTX-253 program in Q4 this year, NTX-529 IND-enabling studies should start shortly, NTX-819 is expected to complete IND-enabling studies in the coming months, and it continues to prepare dipraglurant for phase II in post-stroke recovery. The company said it raised $2.8 million in Q3 through its ATM facility, providing cash runway into Q4 2027, and that patents filed in 2024, if granted, are expected to expire in 2044.
- Balance Sheet Strengthened and Runway ExtendedAddex raised $2.8 million through its ATM facility in Q3, providing a cash runway into Q4 2027.
- Regained Full Rights to GABAB PAM PlatformAddex regained all rights to its GABAB PAM substance use disorder program from Indivior following termination of the license, giving the company freedom to develop all candidates in any indication and, according to management, the broadest portfolio of GABAB PAM drug candidates in the industry.
- Value and Funding Generated Through Indivior CollaborationThe Indivior collaboration provided approximately $20 million in funding, enabled extensive medicinal chemistry and biology work, and produced more than five clinical candidates, including the candidate that completed IND-enabling GLP toxicology studies and is ready for IND filing.
- GABAB PAM Substance Use Disorder Program Ready for IND FilingThe GABAB PAM drug candidate for substance use disorders successfully completed IND-enabling studies and is ready for IND filing and Phase I clinical trials. Supporting preclinical findings included reduced alcohol self-administration and relapse in rats, reduced alcohol consumption in mice, and reduced cocaine self-administration in non-human primates.
- Chronic Cough Candidate Demonstrated Preclinical Efficacy and TolerabilityThe chronic cough candidate showed a consistent minimum effective dose of 1 mg/kg and an ED50 of 6 mg/kg in a guinea pig cough model. At maximal doses, compound A reduced cough numbers by 70%, showed no marked respiratory-rate changes up to 60 mg/kg, and demonstrated a more than 60-fold safety margin based on respiratory depression as a sedation biomarker.
- Chronic Cough Program Showed Durable Effects Without ToleranceIn a seven-day guinea pig study, compound A showed no signs of tolerance in cough frequency or latency to first cough, with no changes in respiratory rate, body temperature, or growth hormone release. In an IPF-related exacerbated cough model, 28-day treatment produced a robust and enduring 40%-60% reduction in cough numbers.
- Chronic Cough Candidate Reduced Fibrosis Measures in Preclinical ModelIn the IPF-related guinea pig model, chronic administration of compound A was associated with markedly lower Ashcroft scores and a lower percentage of affected lung compared with bleomycin-exposed vehicle-treated animals, suggesting reduced lung fibrosis.
- Non-Human Primate Cough Data Confirmed EfficacyIn a citric acid-induced cough model in non-human primates, compound A demonstrated a more than 60% reduction in the number of coughs at 2 mg/kg. The company stated that the candidate has favorable efficacy, tolerability, pharmacokinetic/pharmacodynamic, and developability profiles.
- Chronic Cough IND-Enabling Work Is Ready to Begin Subject to FinancingPre-IND activities, including in vivo proof of concept, GLP toxicology, and CMC work, have been completed, and IND-enabling studies are planned and ready to start subject to securing financing.
- Dipraglurant Repositioned for Brain Injury RecoveryAddex continues to develop dipraglurant, its proprietary mGlu5 negative allosteric modulator, for brain injury recovery. The company has access to intellectual property covering stroke and traumatic brain injury and is collaborating with Syntxis and Lund University on preclinical profiling and preparation for clinical studies.
- ADX-71149 Rights and Development Assets RegainedAddex regained rights to ADX-71149 from Janssen Pharmaceuticals, along with a high-value dataset and significant GMP material. The company is evaluating therapeutic indications and discussing the asset with potential partners.
- Neurosterix Pipeline Continued to AdvanceAddex retains a 20% equity interest in Neurosterix. Neurosterix's lead candidate, NTX-253, a highly selective brain-penetrant M4 PAM for schizophrenia, is expected to complete Phase I in Q4 2026. Backup M4 PAM NTX-529 was selected for IND-enabling studies, and the mGlu7 NAM candidate NTX-819 demonstrated robust preclinical anxiolytic and antidepressant-like activity and is expected to complete IND-enabling studies in the coming months.
- Operating Loss Improved Year Over YearThe H1 2026 operating loss was CHF 1.1 million compared with CHF 1.3 million in H1 2025, an improvement of CHF 0.2 million primarily due to reduced outsourced R&D on the GABAB PAM program.
- GABAB PAM Platform Has Broad Indication PotentialAddex stated that GABAB activation has demonstrated relevance across substance use disorders, cough, pain, overactive bladder, and neurodevelopmental disorders, and plans to explore additional indications with potential partners.
- Patent Portfolio Is Young with Potential Protection Through 2044Addex filed five GABAB PAM patents in 2024, with the patents progressing toward grant. Management stated that, if granted, the expected expiration timeframe is 2044.
- Stalicla Advancing Mavoglurant ProgramStalicla is working with NIDA to advance its Phase III program for mavoglurant in cocaine use disorders.
DE:APE1 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 11, 2027 | 2026 (Q4) | ―- | -2.12 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | ―- | -1.36 | ― | |
| Sep 28, 2026 | 2026 (Q2) | ―-1.31 | -2.74 | 52.19% (+1.43) | |
| Jun 25, 2026 | 2026 (Q1) | ―-0.01 | -1.81 | 99.50% (+1.81) | |
| Apr 30, 2026 | 2025 (Q4) | ―-1.34 | -1.81 | 25.90% (+0.47) | |
| Dec 04, 2025 | 2025 (Q3) | ―-0.01 | -2.44 | 99.63% (+2.43) | |
| Sep 30, 2025 | 2025 (Q2) | ―-1.36 | -2.44 | 44.21% (+1.08) | |
| Jun 19, 2025 | 2025 (Q1) | ―- | -1.22 | ― | |
| Apr 25, 2025 | 2024 (Q4) | ―-1.81 | -1.22 | -48.70% (-0.59) | |
| Nov 22, 2024 | 2024 (Q3) | ―- | -3.73 | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
